Point72 Europe (London) LLP Genmab A/S Transaction History
Point72 Europe (London) LLP
- $2.52 Billion
- Q2 2025
A detailed history of Point72 Europe (London) LLP transactions in Genmab A/S stock. As of the latest transaction made, Point72 Europe (London) LLP holds 471,700 shares of GMAB stock, worth $14.2 Million. This represents 0.39% of its overall portfolio holdings.
Number of Shares
471,700Holding current value
$14.2 Million% of portfolio
0.39%Shares
1 transactions
Others Institutions Holding GMAB
# of Institutions
248Shares Held
65.2MCall Options Held
32.5KPut Options Held
55K-
Alliancebernstein L.P. New York, NY10.7MShares$321 Million0.08% of portfolio
-
Orbis Allan Gray LTD Hamilton, D07.92MShares$239 Million1.07% of portfolio
-
Black Rock Inc. New York, NY5.08MShares$153 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il3.57MShares$108 Million0.01% of portfolio
-
Arrowstreet Capital, Limited Partnership Boston, MA3.45MShares$104 Million0.05% of portfolio
About GENMAB A/S
- Ticker GMAB
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 658,292,992
- Market Cap $19.8B
- Description
- Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...